MiRNA137 Mimics Targeting MCL-1 as a Novel Therapeutic Agent in Preclinical Models of Multiple Myeloma

被引：0
|
作者：
Yang, Y. [1 ]
Saha, M. N. [1 ]
Chen, Y. [1 ]
Chang, H. [1 ]
机构：
[1] Univ Hlth Network, Toronto, ON, Canada
来源：
LABORATORY INVESTIGATION | 2014年 / 94卷
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
1922
引用
收藏
页码：468A / 469A
页数：2
相关论文
共 43 条
  • [1] MiRNA137 Mimics Targeting MCL-1 as a Novel Therapeutic Agent in Preclinical Models of Multiple Myeloma
    Yang, Y.
    Saha, M. N.
    Chen, Y.
    Chang, H.
    MODERN PATHOLOGY, 2014, 27 : 468A - 469A
  • [2] Evaluation of Mcl-1 Inhibitors in Preclinical Models of Multiple Myeloma
    Belmonte, Matthew A.
    Adam, Ammar
    Borrelli, Deanna
    Bhavsar, Deepa
    Bebernitz, Christina
    Hird, Alexander
    Secrist, Paul
    BLOOD, 2014, 124 (21)
  • [3] Predicting response to Mcl-1 targeting agents in NSCLC and multiple myeloma
    McEachern, Kristen
    O'Connor, Greg
    Cidado, Justin
    Belmonte, Matthew
    Barry, Evan
    Dry, Hannah
    Secrist, Paul
    Drew, Lisa
    CANCER RESEARCH, 2016, 76
  • [4] miR-137 and miR-197 Induce Apoptosis and Suppress Tumorigenicity by Targeting MCL-1 in Multiple Myeloma
    Yang, Yijun
    Li, Fei
    Saha, Manujendra N.
    Abdi, Jahangir
    Qiu, Lugui
    Chang, Hong
    CLINICAL CANCER RESEARCH, 2015, 21 (10) : 2399 - 2411
  • [5] Preclinical evaluation of novel MCL-1 degrader in in vitro and in vivo cancer models
    Kowalczyk, P.
    Tomczyk, T.
    Arenciba, J.
    Milewicz, M.
    Skalska, J.
    Trebicka, D.
    Poniatowska, K.
    Adamczyk, J.
    Wojcik, K.
    Cottens, S.
    Dobrzanski, P.
    Bista, M.
    Brach, K.
    Drewniak-Switalska, M.
    Tracz, A.
    Pastok, M.
    Gorecka, K.
    Chrzanowska, K.
    Kaczanowska, K.
    Walczak, M.
    ANNALS OF ONCOLOGY, 2022, 33 : S1443 - S1443
  • [6] Multiple myeloma with amplification of chromosome 1q is highly sensitive to MCL-1 targeting
    Slomp, Anne
    Moesbergen, Laura
    Gong, Jia-nan
    Cuenca, Marta
    Borne, Peter von dem
    Sonneveld, Pieter
    Huang, David
    Minnema, Monique
    Peperzak, Victor
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E49 - E50
  • [7] Multiple myeloma with 1q21 amplification is highly sensitive to MCL-1 targeting
    Slomp, Anne
    Moesbergen, Laura M.
    Gong, Jia-nan
    Cuenca, Marta
    von dem Borne, Peter A.
    Sonneveld, Pieter
    Huang, David C. S.
    Minnema, Monique C.
    Peperzak, Victor
    BLOOD ADVANCES, 2019, 3 (24) : 4202 - 4214
  • [8] Preclinical efficacy of sepantronium bromide (YM155) in multiple myeloma is conferred by down regulation of Mcl-1
    Wagner, Verena
    Hose, Dirk
    Seckinger, Anja
    Weiz, Ludmila
    Meissner, Tobias
    Reme, Thiery
    Breitkreutz, Iris
    Podar, Klaus
    Ho, Anthony D.
    Goldschmidt, Hartmut
    Kraemer, Alwin
    Klein, Bernard
    Raab, Marc S.
    ONCOTARGET, 2014, 5 (21) : 10237 - 10250
  • [9] Preclinical evaluation of AMG 176, a novel, potent and selective Mcl-1 inhibitor with robust anti-tumor activity in Mcl-1 dependent cancer models
    Caenepeel, Sean R.
    Belmontes, Brian
    Sun, Jan
    Coxon, Angela
    Moody, Gordon
    Hughes, Paul E.
    CANCER RESEARCH, 2017, 77
  • [10] The discovery and preclinical characterization of AMG 176: A first-in-class Mcl-1 inhibitor in clinical development for multiple myeloma
    Hughes, Paul E.
    CANCER RESEARCH, 2017, 77
12345